Investment Pitches

Pitch Summary:
Healthpeak Properties presents an attractive investment opportunity due to its diversified portfolio and strategic merger with Physicians Realty Trust. The company has successfully integrated its life sciences and CCRC platforms with a substantial medical office footprint, creating a robust REIT with significant rental income from diverse sources. Despite market concerns about lab space vacancies and rising interest rates, Healthpeak's strong balance sheet, high occupancy rates, and strategic positioning in outpatient medical buildings and senior housing provide a solid foundation for future growth. The stock's current valuation offers a compelling entry point, with a high dividend yield and potential for price appreciation as market conditions improve.

BSD Analysis:
Healthpeak's strategic merger has expanded its footprint to 52 million square feet, enhancing its bargaining power with health systems and increasing its internal management capabilities. The company's outpatient medical buildings, which contribute over half of its rental income, benefit from stable demand and limited new supply due to rising construction costs and tighter credit conditions. Healthpeak's lab portfolio, while facing short-term challenges, remains well-positioned for long-term growth given the U.S.'s dominance in drug discovery and potential policy support for domestic bioproduction. The company's senior housing assets are experiencing a recovery, driven by demographic trends and limited new supply. Healthpeak's financial stability is underscored by its mostly fixed-rate debt and strong liquidity position, allowing it to navigate interest rate fluctuations and pursue strategic opportunities. Overall, Healthpeak's diversified portfolio, strong cash flow generation, and attractive valuation make it a compelling investment in the healthcare REIT sector.

Pitch Summary:
Granite Construction is positioned for continued growth due to its strategic focus on both organic expansion and acquisitions. The company has demonstrated resilience with a 130.3% stock increase since March 2023, outperforming the broader market. Despite mixed recent financial results, the company's valuation remains attractive, and its growth prospects are supported by increased public and private sector investments in infrastructure.

BSD Analysis:
Granite Construction's financial performance in Q1 2025 showed a revenue increase of 4% year-over-year, driven by private sector growth and favorable weather conditions. The company's strategic acquisitions, such as Dickerson & Bowen, have bolstered its revenue streams. While profitability faced challenges due to increased SG&A expenses, adjusted net profits turned positive. The company's forward-looking estimates suggest robust growth, with expected revenue between $4.2 billion and $4.4 billion for the year, and an EBITDA margin of 11% to 12%. Granite Construction's valuation metrics, such as a P/E ratio of 18.7 and an EV/EBITDA of 10.9, indicate it is priced attractively compared to peers. The company's focus on geographic expansion and automation, coupled with a strong backlog of public sector projects, positions it well for future growth. However, investors should be mindful of risks related to political uncertainty and contract pricing structures.

Pitch Summary:
HighPeak Energy is in the process of refinancing its debt, aiming to replace its term loan with a new credit facility and senior notes. The company faces challenges in securing favorable terms for its proposed $725 million senior notes due 2030, which could lead to alternative financing strategies, such as issuing equity. The estimated value of HighPeak's shares is around $10.50, assuming successful issuance of the notes, but could drop to $10 if equity issuance becomes necessary.

BSD Analysis:
HighPeak Energy's refinancing efforts are critical as it seeks to manage its $1.05 billion term loan due in 2026. The company's ability to secure a new revolving credit facility with a lower interest rate could result in significant interest savings, potentially around $15 million annually. However, the delay in pricing the new notes suggests potential difficulties in obtaining favorable terms, possibly due to market conditions or the company's credit profile. HighPeak's proved developed reserves, with a PV-10 of $1.848 billion, provide a strong asset base, but the company's lower capex budget in 2025 may not fully replace these reserves. If HighPeak is forced to issue equity to reduce debt, it could dilute existing shareholders but improve the company's debt coverage ratio. The company's valuation is sensitive to oil price assumptions, with long-term projections of $70 WTI oil supporting its current estimated share value.

Pitch Summary:
NXP Semiconductors is strategically positioned to capitalize on the growing demand for advanced driver-assistance systems (ADAS) and autonomous driving technologies. The company holds a dominant position in the automotive semiconductor market, particularly in radar transceivers and battery management systems. Despite recent economic headwinds and trade concerns, NXP's management anticipates a rebound in activity, supported by improving distribution channels and customer backlogs. The company's focus on innovation and strategic acquisitions further strengthens its competitive edge. With a projected revenue growth of 8% CAGR and a target price of $255 per share, NXP presents a compelling investment opportunity.

BSD Analysis:
NXP's robust market share in automotive semiconductors positions it well to benefit from the increasing adoption of ADAS and autonomous vehicles. The company's strategic acquisitions, such as Aviva, TTTech, and Kinara, enhance its capabilities in software-defined vehicles, aligning with industry trends. Financially, NXP maintains a healthy balance sheet with a reasonable net debt to EBITDA ratio of 1.6x, supporting continued shareholder returns through buybacks and dividends. The anticipated gross margin expansion to 60% and a doubling of free cash flows by 2030 underscore management's confidence in its growth trajectory. However, the competitive landscape remains intense, with pressure from both established players and emerging Chinese firms. NXP's success will hinge on its ability to innovate and capture market share in the evolving semiconductor industry. Overall, the stock's valuation, supported by a DCF analysis, suggests significant upside potential, making it an attractive buy for long-term investors.

Pitch Summary:
Fortinet is positioned for significant growth through its transition to a subscription-led business model, leveraging its strong firewall market share and expanding AI capabilities. The company's unified platform approach is expected to drive substantial ARR growth, supported by a disciplined balance sheet and share repurchase program. With a target price of $148, Fortinet offers a compelling investment opportunity with a strong margin of safety.

BSD Analysis:
Fortinet's strategic shift towards a subscription-based revenue model is expected to enhance its operating leverage, driving EPS growth well above consensus estimates. The company's focus on AI integration within its Security Fabric positions it as a leader in the cybersecurity space, with potential for significant competitive advantage. Fortinet's robust free cash flow generation, coupled with a disciplined share buyback strategy, further strengthens its financial position. Despite potential risks from geopolitical tensions and competitive pressures, Fortinet's strong product cycles and recurring revenue streams provide a solid foundation for long-term growth. The company's valuation, based on a 50x FY26E P/E, reflects its growth prospects and offers substantial upside potential compared to historical and peer multiples.

Pitch Summary:
The SPDR S&P Semiconductor ETF (XSD) offers a diversified exposure to the semiconductor industry, which is currently experiencing strong performance, particularly among small- and mid-cap stocks. Despite a high P/E ratio, the ETF's robust growth prospects, driven by the ongoing AI boom, make it an attractive investment. The fund's equal-weighted approach reduces concentration risk, providing a balanced exposure to the sector.

BSD Analysis:
XSD's portfolio leans towards growth, with a significant allocation to domestic small- and mid-cap stocks, which are more cyclical compared to large-cap peers. The ETF's high P/E ratio of 29 is offset by a solid long-term EPS growth rate of over 14%, resulting in a reasonable PEG ratio of around 2. Despite recent volatility, the ETF has shown strong technical momentum, with shares approaching all-time highs. The fund's liquidity is mixed, with low average daily volume and a moderate bid/ask spread, suggesting the use of limit orders for trading. As the semiconductor industry continues to benefit from technological advancements and AI developments, XSD remains well-positioned for potential upside, with a long-term target price of $390 based on technical analysis.

Pitch Summary:
Champion Homes presents a compelling investment opportunity due to its strong market position in the affordable housing sector, particularly in modular homes. Despite recent earnings misses and margin pressures, the company maintains robust financial health with a significant net cash position and a conservative debt-to-equity ratio. The current stock price, down significantly from its 52-week high, offers an attractive entry point as the company is poised for margin recovery and growth in the expanding modular housing market.

BSD Analysis:
Champion Homes' recent acquisition of Regional Homes has temporarily inflated SG&A expenses, impacting margins. However, this is expected to normalize, providing a catalyst for margin recovery. The company's strategic positioning in the Southeast, a rapidly growing region, and its vertically integrated business model enhance its competitive edge. With a market cap of $3.59 billion and an EV/EBITDA of 10.75, Champion Homes trades at a discount compared to peers like Cavco Industries, suggesting an attractive risk-reward profile. The ongoing $100 million share repurchase program further underscores management's confidence in the company's valuation. As the modular housing market is projected to nearly double by 2032, Champion Homes is well-positioned to capitalize on the increasing demand for affordable housing solutions.

Pitch Summary:
Primerica stands out in the insurance sector due to its focus on term life policies and investment products, which generate recurring fee income rather than relying heavily on interest income or mortality risk. The company's business model, which includes reinsuring a significant portion of its mortality risk, allows it to maintain a capital-light structure. This enables Primerica to return substantial capital to shareholders through buybacks and dividends. Despite recent pressures on term-life sales due to economic conditions, Primerica's investment services have shown robust growth, supporting overall revenue expansion. With a strong balance sheet and a high return on equity, Primerica is well-positioned for long-term growth, making it an attractive investment at its current valuation.

BSD Analysis:
Primerica's strategic focus on term life insurance, which is less capital-intensive due to its reinsurance strategy, allows the company to maintain a robust capital position with a risk-based capital ratio of 470%. This financial strength supports its aggressive capital return strategy, including a 5% reduction in share count over the past year and a 1.5% dividend yield. The company's investment services segment has shown impressive growth, with a 25% increase in sales revenue and an 18% rise in asset-based revenue, driven by favorable product mix and sponsor contracts. Primerica's ability to generate a 30% return on equity, despite slower term-life sales, underscores its operational efficiency and the resilience of its business model. Given the current market conditions and the potential for continued growth in its investment services, Primerica's shares, trading at a ~12.8x multiple, offer a compelling opportunity for long-term investors seeking stable returns with a blend of income and growth potential.

Pitch Summary:
Colgate-Palmolive, a leader in consumer goods, has shown resilience despite challenges such as declining volumes and currency headwinds. While its valuation has moderated from previous highs, the stock remains slightly overvalued compared to historical averages. The company continues to deliver stable returns through dividends and share buybacks, supported by its strong brand portfolio and strategic focus on high-margin products. However, current market conditions and geopolitical risks suggest a cautious approach, with potential for better entry points in the future.

BSD Analysis:
Colgate-Palmolive's current valuation, with a P/E ratio of 25.4, is slightly above its 10-year average, indicating a fair to slight overvaluation. The company's strategic shift away from low-margin private label products has improved gross margins, but volume growth remains a concern, particularly in the US market. The company's strong cash flow generation supports its dividend yield of 2.2%, which is slightly below its historical average, and its ongoing share buyback program. Despite these strengths, the company faces headwinds from potential tariffs and geopolitical tensions, which could impact sales. The pet nutrition segment, growing at a CAGR of 7.1%, offers a bright spot, contributing significantly to revenue growth. Overall, while Colgate-Palmolive remains a solid long-term investment, investors may find more attractive entry points as market conditions evolve.

Pitch Summary:
CoreWeave, Inc. has experienced a significant price increase since its IPO, driven by strong demand for its data center services in the AI sector. The company's reliance on debt rather than equity for growth has minimized dilution risk, although stock-based compensation remains high. While the stock has delivered exceptional returns in the short term, future gains are expected to moderate, with a projected 33.3% upside from the current price. However, the potential for downside risk, including revenue concentration and high debt levels, suggests a more cautious approach is warranted.

BSD Analysis:
CoreWeave's business model capitalizes on the growing demand for AI infrastructure, positioning it as a key player in the sector. The company's strategic decision to use debt financing has helped avoid immediate equity dilution, but its high stock-based compensation and potential future equity issuance pose risks. The concentration of revenue from major clients like Microsoft and OpenAI highlights the company's dependency on a few large customers, which could impact financial stability if these relationships change. Despite a robust market position, CoreWeave's significant debt burden and limited cash reserves present financial challenges. The company's future performance will depend on its ability to maintain its competitive edge in the rapidly evolving AI infrastructure market. Given these factors, while the stock has potential for moderate gains, the risks suggest a hold strategy as the market adjusts to more sustainable growth rates.

Pitch Summary:
Singularity to plurarity. We have increasingly found that some of the best long-term compounders start deep with a singular product or service in one market, providing significant customer value and being profitable on a unit economic level, often expand to include more products or services and to more similar markets and geographies. The additional layered products and services typically strengthen the network effects, making the product or service stickier, driving higher customer retention, usage, reliance, and the willingness to spend more. Over time, this results in one of n, where the company becomes significantly larger... There are numerous examples in our fund... Palantir, from data integration and analysis with government agencies to enterprises.

BSD Analysis:
Palantir is a high-stakes, high-conviction AI software powerhouse whose value is locked in the successful monetization of its Artificial Intelligence Platform (AIP) across the commercial enterprise. The core thesis is driven by the company's unassailable dominance in AI-powered operational decision-making, which allows complex organizations to move beyond simple data analytics to action-driven automation. The AIP Ontology is its true moat, serving as a unified data model that makes complex enterprise data legible to LLMs, thereby minimizing hallucinations and increasing utility. Palantir is leveraging its deep government expertise to sell pre-built AI applications for complex industrial use cases like supply chain logistics, equipment surveillance, and dynamic pricing. The stock is a high-risk, high-reward play on its ability to rapidly monetize its unique AI technology in the private sector.

Pitch Summary:
As always I like to do a deep dive at the end of these letters as a way of surfacing undiscovered names or variant perceptions to you all. Since my first investment in March 2025, MDA Space is up 70% and yet it is only just beginning in my opinion. I have added to my position as recently as June. Overview MDA Space started in 1969 in Vancouver, that is 56 years of innovating in space from before SpaceX existed. Since that time, the company traded hands across various companies and private investors all the while accomplishing amazing feats such as building the Canadarm for the Internation Space Station and building many satellites mostly in GEO (Geostationary Earth Orbit) as pre SpaceX, launch costs were so high that it made sense to build a bigger satellite to cover as many use cases as possible. MDA Space’s revenue comprises of building, deploying and maintaining satellite systems (60% of revenue), space robotics (24% of revenue), and Geointelligence (16% of revenue). Given it’s long history of successfully building satellites, it is trusted by governments, defense, and communication companies around the world. The majority of revenue today comes from Canada and the USA but as more countries look to build up their own space comms networks for defense and national use cases, MDA Space stands to benefit. MDA Space has blue chip customers like the Canadian government, US government, UK Space Agency, Thales (France), Airbus (Europe), Boeing, Lockheed Martin, Telesat, and Globalstar (Apple being the end customer). The company is forecasting growth of 45% YoY, ramping up capex in order to build world class robotic enabled facilities to continue building state of the art satellites and space robotics, and is actually profitable. To make it easy for comparison at $3B EV MDA Space trades at 2.4x NTM Sales and 12.3x NTM EBITDA. Rocket Lab at $17B EV trades at 26.7x NTM Sales with no FWD EBITDA, AST SpaceMobile at $12B EV trades at 144.0x NTM Sales with no FWD EBITDA. In MDA Space, you have a best of breed satellite and space robotics company with the longest operating history in the public company space but because it trades on the Canadian exchange exhibits a steep discount to US Space peers who have less revenue and similar growth. Management Mike Greenley, CEO of MDA Space has extensive experience in the defense tech ecosystem spanning 21 years across CAE, General Dynamics, L3 Technologies, and MDA Space. In his time he has led organizations building sensors, simulation software, military communications, and imaging analytics. All of these are aligned with MDA Space’s key business segments and certainly with the end customers. Cameron Owner, CTO of MDA Space has been at the business for 26 years spanning a career across the space control center, systems engineering, and robotics & automation. He has touched every aspect of the R&D function in his career. The Board of Directors is filled with experience across Space, Defense, and Government but one person that’s worth calling out in particular is Darren Farber, former US Deputy Under Secretary of Defense. For those interested in learning more about the defense industry, Invest Like The Best interviewed Darren in April 2025. Business MDA Space is one of the oldest and trusted manufacturers of space equipment. Three generations of their RADARSAT GEO satellites have been operating successfully since 1995. MDA’s robotic arms have been on the Mars Rovers since 2008 and MDA’s Canadarm has been on the ISS since 2001. MDA Space currently manufactures mostly MEO and LEO satellites (60% of rev). The reason for this is with modern space launches, larger constellations of these two types of satellites can be launched vs GEO satellites are typically much larger in size. While the capability of GEO satellites is vast, MEO & LEO satellites are perfect for a larger communication surface area, frequent imaging, and just generally having more satellites in space. Major drivers of Backlog growth continue to be large constellation wins. Globalstar (servicing Apple’s mobile network) and Telesat are the largest wins in recent years. Echostar also plans to launch a constellation and is expected to choose MDA Space as their provider. More government wins are expected and in Q1 2025, MDA Space added another $750M to backlog. For context, SpaceX is building Starlink, Amazon is building Kuiper, and then MDA Space are building Globalstar and Telesat constellations. There are no other major commercial constellations announced outside of Rocket Lab saying they may start to build one in the future. MDA Space develops space robotics, rovers and sensors (24% of rev). Notably the Canadarm was developed by MDA Space and to this day is still used by the International Space Station to make robotic adjustments to the station and equipment given the risks everything of having an astronaut going into space and doing it themselves. Canadarm 3 is a big robotics project that the Canadian Space Agency has granted to MDA Space. This is supposed to be attached to the Lunar Gateway, the new International Space Station. However, with proposed NASA budget costs this could be at risk in 2026 or beyond. The risk is mitigated though by the fact that the ISS is a core feat not only of engineering but collaboration between many different countries and it seems unlikely that the US would pull away from that. At 16% of rev, MDA Space provides Geointelligence. This is analytics, imaging, and data from satellites used for everything from climate to defense to hedge funds. Of note, anytime MDA Space launches more satellites, Geointelligence benefits with a lag. The reason being, you can’t sell more analytics if you don’t have the satellites in space to provide them. So Geointelligence is a bit of a lagging revenue generator. So when MDA Space is in scaling mode, margins will look lower than steady state as development of the satellites is hitting before the software and data revenue comes in. One final thing to note, is a lot of what MDA Space builds hardware wise is “recurring” in nature. LEO satellites burn up fairly quickly being close to the earth’s atmosphere or even just having wear & tear from space debris. MDA Space is also advancing the technology of satellites at a rapid pace and so you have a 5-6 year refresh cycle from wanting to get new tech up into space and also needing to replace the previous satellites to maintain connectivity. Competitive Positioning SpaceX and Amazon are competitors (although ironically Blue Origin is a customer of MDA Space). However, each are building constellations for their own use cases while MDA is a standalone trusted provider to anyone who wants to launch a satellite. Given geopolitical dynamics, governments, corporations, and defense industries around the world are wondering if they should entrust their space systems to anyone company. This bodes well for MDA as they already work with European countries and corporations. Furthermore, a potential risk would be if one day SpaceX said they would refuse to put other satellite payloads up into space. This would be counter to SpaceX’s business model as while Starlink is definitely a huge current and future revenue generator, payloads and utilization of the rockets is core to making each launch exhibit compelling economics. As the cost curve for launches continues to decrease, MDA Space will continue to benefit from increased demand and better margins. Reason to Own There are very few opportunities to own a leading and trusted manufacturer of critical technologies with high barriers to entry at a cheap valuation. MDA Space hits all that criteria. They have massive tailwinds that should continue to reflect high growth for many years to come. They continue to push the satellite industry forward by developing new technology and have a proven and demonstrated track record of delivering durable systems for over 55 years. Package that up with a valuation that is meaningfully cheaper than peers and MDA Space represents a highly compelling high growth, tech advantaged investment opportunity.

BSD Analysis:
MDA Space is a vertically integrated space infrastructure company with leading positions in satellites, robotics and geointelligence, giving it a diversified but synergistic revenue base. Backlog growth driven by large constellation awards from customers like Globalstar and Telesat underpins the guided ~45% top-line growth and supports the current capex ramp. At roughly 2–3x forward sales and low-teens EV/EBITDA, the stock trades at a steep discount to U.S.-listed space peers such as Rocket Lab and AST SpaceMobile that have less revenue scale and no forward EBITDA. The inherent refresh cycle of LEO constellations, along with ongoing innovation in satellite technology, makes much of the hardware effectively recurring over 5–6 year intervals. Key risks include potential NASA budget pressure on Canadarm 3, execution on major programs and launch bottlenecks, but structural demand for sovereign and commercial space communications provides a strong multi-year tailwind. Overall, the combination of durable competitive advantages, visible growth and discounted valuation makes the risk/reward particularly attractive.

Pitch Summary:
Prime U.S. defense contractor with four segments (Aero, MFC, RMS, Space). Despite F-35 noise and lost 6th-gen fighter, author argues multi-decade sustainment cash flows, restocking demand (Ukraine/ME), rising allied budgets (NATO), hypersonics/space growth, and potential U.S. “Golden Dome” missile defense create durable earnings; trades ~16–17x ’25 EPS with ~3% yield.

BSD Analysis:
Setup is classic defense: high correlation to DoD outlays, international mix rising, and long-tail sustainment offsets procurement lumpiness. Key watch items: execution in MFC post classified charge, F-35 modernization cadence, and backlog conversion vs. supply chain. Risk: budget/political shifts or faster drone-centric disruption, but scale and M&A history favor LMT.

Pitch Summary:
Small-cap aerospace components manufacturer with 3 units (forging, electronics, castings). CEO Dave Robbins (ex-Micronetics) seen as strong operator. DP Cast underperformed post-acquisition but nearing breakeven with Pratt & Whitney contract renewal; Monzite (electronics) has high-margin growth potential. Consolidated adj. EBITDA swung from loss (2022) to +$1.5M (2024). EV ~$11M (net cash + stake in Cal-Nano worth ~$3M). Author sees multi-bagger potential if management executes and avoids poor M&A.

BSD Analysis:
Interesting micro-cap aerospace recovery play. Core thesis: strong operator, aerospace tailwinds, undervalued EV with hidden assets (Cal-Nano). Risks: governance conflicts, prior poor M&A (DP Cast), lumpy electronics results. Upside if margins expand and backlog converts cleanly; downside is execution risk at this small scale.

Pitch Summary:
Post-OM2 pivot from bio-PX to patented thermoformed PET closures enabling mono-material, fully recyclable bottles (tethered-cap ready). Pilot line shipping samples; >20 customers in qualification, one $100mm MOU. Guide: $50–70mm ’26 rev, $150–210mm ’27; EBITDA breakeven 2H26 with 8–10 lines. Trades below net cash; upside 2–6x if execution/financing land; key risks are dilution, scale-up/quality timing, and customer qual timelines.

BSD Analysis:
Compelling asymmetric: real pain from failed SPAC plan, but the closures pivot solves a clear industry need with IP moat and regulatory tailwinds. Financing overhang likely forces dilution, yet even doubled share count can still yield multi-bagger if 2026–27 targets are hit. Watch FAT/line ramps, first commercial shipments, and any licensing that could fund growth with low capex.

Pitch Summary:
Prime U.S. defense contractor with four segments (Aero, MFC, RMS, Space). Despite F-35 noise and lost 6th-gen fighter, author argues multi-decade sustainment cash flows, restocking demand (Ukraine/ME), rising allied budgets (NATO), hypersonics/space growth, and potential U.S. “Golden Dome” missile defense create durable earnings; trades ~16–17x ’25 EPS with ~3% yield.

BSD Analysis:
Setup is classic defense: high correlation to DoD outlays, international mix rising, and long-tail sustainment offsets procurement lumpiness. Key watch items: execution in MFC post classified charge, F-35 modernization cadence, and backlog conversion vs. supply chain. Risk: budget/political shifts or faster drone-centric disruption, but scale and M&A history favor LMT.

Pitch Summary:
World’s largest food & beverage company (pet care + coffee = 46% of sales). Valuation has de-rated; new insider CEO pivoting from M&A to “back to basics”: fix underperformers, boost A&M to ~9%, €2.5B cost saves to 2027. FCF yield ~6.8% ex-L’Oréal stake and ~4% dividend targeted to drive LSD/HSD TSR as volumes recover post pricing cycle. Risks: FX (CHF), commodity volatility (coffee/cocoa), past M&A missteps.

BSD Analysis:
Defensive quality at a more reasonable multiple; upside from margin/volume normalization, disciplined capital allocation, and optionality around the ~20% L’Oréal stake. Not flashy, but a credible path to low double-digit compounding with limited terminal risk.

Pitch Summary:
Kura Oncology is poised for significant growth due to its promising drug pipeline, particularly its lead candidate, ziftomenib, which targets relapsed/refractory NPM1-mutated and KMT2A-rearranged acute myeloid leukemia (AML). The company has submitted a New Drug Application (NDA) for ziftomenib as a monotherapy, which has been granted Priority Review by the FDA, with a decision expected by November 30, 2025. Additionally, Kura is advancing ziftomenib into phase 3 trials as part of combination therapies for newly diagnosed AML patients, expanding its potential market reach.

BSD Analysis:
Kura Oncology's strategic focus on targeting specific genetic mutations in AML positions it well within the growing oncology market. The global AML treatment market is projected to reach $6.1 billion by 2028, and Kura's ability to address up to 50% of the AML patient population with its menin inhibitor, ziftomenib, is a significant opportunity. The company's collaboration with Kyowa Kirin enhances its development capabilities and financial stability, as evidenced by a pro forma cash balance of $703.2 million, sufficient to fund operations into 2027. The positive data from the KOMET-007 trial, showcasing high response rates in combination therapies, underscores the potential for ziftomenib to improve standard care outcomes. However, investors should be mindful of regulatory risks and the competitive landscape in oncology drug development. Overall, Kura's innovative approach and robust pipeline make it a compelling investment in the biotech sector.

Pitch Summary:
Yext has shown signs of stabilizing its recurring revenue and improving profitability, driven by its new AI product, Yext Scout. Despite these positive developments, the company faces significant challenges, including strong competition and a history of poor customer retention. While its valuation appears attractive, these risks temper the investment case, warranting a cautious approach.

BSD Analysis:
Yext's valuation at 8.7x adjusted EBITDA suggests a potentially undervalued opportunity, especially with its recent guidance increase and the promising early interest in Yext Scout. However, the company's competitive landscape is intense, with rivals like Qualtrics and Chattermill posing significant threats. Yext's retention rates, although improving, remain a concern, reflecting ongoing customer churn. The company's growth has been partly fueled by acquisitions, such as Hearsay Systems, rather than organic expansion. Investors should watch for further developments in Yext Scout's adoption and any strategic moves to enhance customer retention and organic growth. Given these dynamics, Yext may offer upside potential, but it requires vigilant monitoring for any shifts in its competitive position or financial performance.

Pitch Summary:
British American Tobacco's recent developments present a mixed picture. The company's Glo Hilo heated tobacco device has not met expectations, with limited market launches and consumer feedback indicating issues with the product. However, the nicotine pouch segment, particularly with the Velo Plus product, shows significant promise with high growth and profit margins. The core tobacco business remains strong, providing a stable foundation for the company.

BSD Analysis:
British American Tobacco's valuation remains attractive, trading at a low P/E ratio of 9.46x and offering a 7% dividend yield, which provides a margin of safety for investors. The company's traditional tobacco products continue to generate steady cash flows, which is crucial as it navigates the challenges and opportunities in the next-generation product space. The nicotine pouch market, especially in the US, is a key growth area, with Velo Plus potentially capturing significant market share due to its favorable consumer reception and high margins. While the Glo Hilo device has underperformed, the company's ability to innovate and adapt in the nicotine alternatives market could drive future growth. Investors should monitor management's communication and execution on these new product lines, as transparency and strategic clarity will be essential for maintaining investor confidence.